Last reviewed · How we verify
Nab-paclitaxel+ trastuzumab+ patuzumab
Nab-paclitaxel+ trastuzumab+ patuzumab is a Microtubule inhibitor and HER2-targeting monoclonal antibodies Small molecule drug developed by Henan Cancer Hospital. It is currently in Phase 3 development for Adjuvant treatment of HER2-positive breast cancer, Metastatic breast cancer with HER2 overexpression. Also known as: nab-PHP regimen group.
Nab-paclitaxel is a microtubule inhibitor that disrupts cell division, while trastuzumab and pertuzumab are monoclonal antibodies that target the HER2 protein.
Nab-paclitaxel is a microtubule inhibitor that disrupts cell division, while trastuzumab and pertuzumab are monoclonal antibodies that target the HER2 protein. Used for Adjuvant treatment of HER2-positive breast cancer, Metastatic breast cancer with HER2 overexpression.
At a glance
| Generic name | Nab-paclitaxel+ trastuzumab+ patuzumab |
|---|---|
| Also known as | nab-PHP regimen group |
| Sponsor | Henan Cancer Hospital |
| Drug class | Microtubule inhibitor and HER2-targeting monoclonal antibodies |
| Target | Microtubules and HER2 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Nab-paclitaxel works by binding to tubulin and preventing the formation of microtubules, which are essential for cell division. Trastuzumab and pertuzumab, on the other hand, bind to the HER2 protein on the surface of cancer cells, preventing the growth and proliferation of these cells.
Approved indications
- Adjuvant treatment of HER2-positive breast cancer
- Metastatic breast cancer with HER2 overexpression
Common side effects
- Neutropenia
- Fatigue
- Nausea
Key clinical trials
- Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer (PHASE3)
- Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC (PHASE2)
- A Comparison of Nab-PHP and TCbHP Efficacy in Neoadjuvant Therapy for HER2-positive Early Breast Cancer (PHASE3)
- Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nab-paclitaxel+ trastuzumab+ patuzumab CI brief — competitive landscape report
- Nab-paclitaxel+ trastuzumab+ patuzumab updates RSS · CI watch RSS
- Henan Cancer Hospital portfolio CI
Frequently asked questions about Nab-paclitaxel+ trastuzumab+ patuzumab
What is Nab-paclitaxel+ trastuzumab+ patuzumab?
How does Nab-paclitaxel+ trastuzumab+ patuzumab work?
What is Nab-paclitaxel+ trastuzumab+ patuzumab used for?
Who makes Nab-paclitaxel+ trastuzumab+ patuzumab?
Is Nab-paclitaxel+ trastuzumab+ patuzumab also known as anything else?
What drug class is Nab-paclitaxel+ trastuzumab+ patuzumab in?
What development phase is Nab-paclitaxel+ trastuzumab+ patuzumab in?
What are the side effects of Nab-paclitaxel+ trastuzumab+ patuzumab?
What does Nab-paclitaxel+ trastuzumab+ patuzumab target?
Related
- Drug class: All Microtubule inhibitor and HER2-targeting monoclonal antibodies drugs
- Target: All drugs targeting Microtubules and HER2
- Manufacturer: Henan Cancer Hospital — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Adjuvant treatment of HER2-positive breast cancer
- Indication: Drugs for Metastatic breast cancer with HER2 overexpression
- Also known as: nab-PHP regimen group
- Compare: Nab-paclitaxel+ trastuzumab+ patuzumab vs similar drugs
- Pricing: Nab-paclitaxel+ trastuzumab+ patuzumab cost, discount & access